Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company that develops RNA-based medicines to restore protein expression in severe genetic diseases. Its news flow is closely tied to the progress of its antisense oligonucleotide programs, particularly zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Investors following STOK news can expect regular updates on clinical development milestones. These include announcements on the global Phase 3 EMPEROR study of zorevunersen in children and adolescents with Dravet syndrome, multi-year data from open-label extension studies, and analyses comparing treated patients with natural history data. Stoke also reports on natural history research such as the FALCON study in ADOA, which informs the design of interventional trials like the OSPREY Phase 1 study of STK-002.
Regulatory and collaboration developments are another important category of news. Stoke highlights regulatory designations for zorevunersen, including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, as well as its strategic collaboration with Biogen, under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights.
Corporate and financial updates appear in press releases and are often paired with SEC filings. These items cover quarterly financial results, cash runway commentary, stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in major healthcare and investor conferences. Webcasts and conference calls for analysts and investors are also announced through news releases.
For anyone researching STOK, the news stream provides context on how Stoke Therapeutics is advancing its TANGO antisense platform, executing clinical trials in rare neurological and ophthalmic diseases, and managing its partnerships and capital to support ongoing development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Stoke Therapeutics (Nasdaq: STOK) has received authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial (OSPREY) for STK-002, targeting autosomal dominant optic atrophy (ADOA), a rare inherited optic nerve disorder causing vision loss. The study aims to assess the safety and efficacy of STK-002, designed to upregulate OPA1 protein expression and potentially halt vision deterioration. Enrollment for the trial is expected to begin in early 2024. Currently, there are no approved treatments for ADOA, affecting approximately 1 in 30,000 people globally. Stoke's approach leverages the TANGO platform, focusing on treating haploinsufficiencies and CNS diseases.
FAQ
What is the current stock price of Stoke Therapeutics (STOK)?
What is the market cap of Stoke Therapeutics (STOK)?
